In the world of biotech and medtech, where capital is hard-won, timelines are long, and scientific uncertainty looms large, a quiet revolution is reshaping how breakthrough companies get built. Rather than relying solely on traditional venture capital, a growing number of founders, investors, and institutional backers are embracing the venture studio model—a hands-on, build-to-invest approach designed to reduce risk, increase speed to market, and strengthen operational execution from day one.
This model is gaining serious traction across life sciences, especially in markets that demand both scientific rigor and entrepreneurial muscle. As recent data and new studio entrants show, this shift isn’t just cosmetic—it’s systemic, and it may be one of the most important structural evolutions in early-stage life science innovation in decades. Studio models are now carving out a dynamic niche alongside traditional VC.
A Doubling in Demand—and It’s Just the Beginning
The latest analysis from Decile Group underscores this milestone shift. While venture studio funds accounted for just 6 percent of all new emerging VC funds in 2024, that share has more than doubled to 13 percent in 2025. This rapid ascent marks a breakthrough moment for the model—and one that demands the attention of GPs and LPs alike.
What explains the surge? It lies in the model’s unique pairing of capital and operational leverage. As the report notes, unlike traditional VC funds, where capital is allocated to founders after a startup is formed, studio funds deploy capital directly into startups the team has helped create. That early alignment yields clearer fund theses and more predictable pipelines—a meaningful edge when attracting LPs seeking signal and structure in uncertain markets.
Lean Goals, Stronger Traction
Another compelling layer: venture studios typically run lean. They target an average fund size of $6.4 million—smaller than both accelerator funds ($7.7 million) and traditional funds ($10.6 million). Yet, for all their modest ambitions, these studio funds outperform peers in early traction.
Within 6 to 12 months of fundraising, they secure an average of $2.8 million in soft commitments (non-binding letters of intent), nearly 3× more than accelerator funds ($0.9 million) and significantly higher than traditional funds ($2.2 million). Moreover, these studios typically close on 50 percent of their fundraising targets in that time—versus just 16 percent for accelerators and 31 percent for traditional VC. That speed and clarity resonate with LPs.
Greater Control, Tighter Execution
Venture studios offer more than capital—they deliver control. From idea incubation to team assembly, studios embed operational rigor into the earliest stages. Decile highlights that this alignment gives GPs greater control over portfolio design and startup quality, while offering LPs clearer visibility into how their capital will be used.
But this control comes with tradeoffs: the model demands intensive operational involvement, which can limit scale; unfamiliar LPs may perceive it as niche; and fund–studio economics can create internal conflicts. Still, for GPs with execution muscle, that tradeoff can be a feature, not a bug.
Who’s Leading the Charge—and Where They’re Investing
Examining leadership and focus, the venture studio model attracts a spectrum of operators. About 53 percent of studios are led by solo GPs and 47 percent by teams, reflecting flexibility in structure. Most GPs fall in the 40–50 age range (40 percent), with 30 percent younger and 30 percent older. Notably, diversity remains limited: 86 percent of studio funds are led by all-male teams; mixed-gender teams account for just 11 percent, and all-female teams 3 percent, compared to 31 percent women-led across emerging fund types.
Finally, sector specialization defines the studios’ strategic edge. Sixty-five percent focus on a single vertical—far higher than generalists (15 percent)—with leading sectors including AI (28 percent), software (16 percent), B2B (13 percent), deep tech (9 percent), and impact (9 percent).
Taken together, the emergence of venture studio funds signals a meaningful recalibration in the early-stage ecosystem. Their formula of operational immersion, lean capital, and defined vision is winning attention—and early-stage dollars.
Who’s Writing the Checks: LP Interest
Broader patterns from the emerging manager ecosystem offer important clues—and now, growing evidence to what LPs are writing checks. Decile’s broader “Venture 2.0” states that Fund I capital in early studio or emerging venture funds typically flows from founder networks, successful angel investors, and sector-aligned operators. However, beyond these roots, venture studios are beginning to gain traction with a wider set of limited partners—including family offices and institutional investors.
Recent research shows that 21 out of 25 surveyed investors (including family offices and HNWIs) are actively considering venture studios in their strategy—though only two currently prioritize them. Investment sizes vary widely, from under $500K to over $5 million, reflecting an exploratory but diverse set of backers beginning to enter the space.
Even among investors who have previously funded studios, 75 percent say they are still testing the model rather than allocating significant capital—suggesting room for deeper participation as performance data matures and reporting becomes standardized.
On the institutional side, structured frameworks like the Venture Studio Index (VSI) are helping LPs—from foundations to pension funds—evaluate studio models through a lens of governance, transparency, and operational scalability. Analysts have noted that venture studios’ ability to de-risk early-stage ventures, control ownership, and streamline product-market fit has started to appeal to institutions seeking new alpha-generating strategies.
Moreover, the studio structure enables greater equity retention and capital efficiency, two qualities that are increasingly aligned with long-term institutional mandates in a capital-constrained VC environment.
In short, while the model may have started with insiders and operators, it is now quietly drawing interest from some of the most sophisticated capital sources in the venture landscape. For LPs who want sharper control, clearer theses, and earlier access to high-conviction opportunities, the venture studio model is quickly becoming more than an experiment—it’s becoming a strategy.
Four Venture Studios You Should Know
Emerging Technology Centers (ETC Baltimore) — A nonprofit venture studio anchored in Baltimore that supports regional tech, biotech, and medtech companies, bolstering founder ecosystems with infrastructure and capital; led by Dr. Arti Santhanam.
Persephoni BioPartners (Research Triangle, NC) — Led by CEO and Founder, Hilary Schultz, this life sciences venture studio partners with academia, investors and industry to streamline early traction and turn breakthrough science into patient-ready impact. Further validating their model is a recently launched a $1.5 million strategic sponsorship with the American Cancer Society’s BrightEdge to accelerate oncology innovation, translating early-stage breakthroughs into clinical-stage candidates.
Linden Lake Labs (Rockville, MD) — Led by CEO Thomas Haag and Co-Founder Abhishake Chhhibber, this studio incubates molecular medicines targeting oncology, CNS/neurodegenerative, and rare diseases—operating via a “hub-and-spoke” structure and offering design, development, scaling, and CMC manufacturing through its portfolio company, Xcellon Biologics.
Concept Bio (New York, NY) — Led by biotech veterans Dr. Alan Horsager and Dr. Cyrus Arman, Concept Bio is a science-first venture studio that partners with founders and researchers to translate breakthrough life science innovations into de-risked, venture-backed companies through hands-on operational and strategic support.
Why This Matters—and What It Means for the Future of VC
- Studio Funds Deliver Faster, More Certain LP Access. By targeting smaller fund sizes and offering built-in operational commitment, studios attract more soft commitments and close more of those targets early—signaling deep LP conviction.
- Operational Control Isn’t Just a Differential—it’s a Hedge. Building startups in-house allows GPs to mitigate early-stage risk, curate founder gaps, and calibrate product execution before raising traditional rounds.
- Specialization Enhances Signal. Focused studio funds in AI, biotech, medtech, or impact offer clarity in thesis and reinforcement in pipeline—traits that LPs and entrepreneurs find compelling.
- Opportunity—and Responsibility—in Leadership. With most studios led by male, mid-career GPs, there’s a clear window to broaden representation. More diverse leadership could unlock innovation and opportunity.
- Nonprofit and Mission-Aligned Studios Are Gaining Traction. ETC’s regional life sciences focus and Persephoni’s mission-driven oncology translation underscore a growing trend: studios with anchoring in social impact, public-sector partnership, and ecosystem development can generate both capital returns and community value.
Summary: Key Takeaways
- Rising Momentum: Venture studio funds have grown from 6% of new emerging VC funds in 2024 to 13% in 2025—more than doubling.
- Capital Efficiency: Studio funds target ~$6.4 million—leaner than peers—but achieve far stronger early traction in soft commitments and fundraising success.
- Control + Clarity: By investing into teams they build, studio GPs deliver operational oversight and clear theses to LPs.
- Focused Leadership, Narrower Diversity: Most studio funds are male-led (86%), team or solo GP structures; there’s scope—and need—for broader inclusion.
- Sector Specialization Rules: Studios favor AI, software, B2B, deep tech, and impact at high rates—enhancing repeatable models and defensible theses.
- Strong Studio Examples:
- ETC Baltimore, nonprofit, regional tech/biotech focus.
- Persephoni BioPartners, launching oncology breakthroughs via a Clinical Impact Studio.
- Linden Lake Labs, incubating advanced molecular medicines with efficient operational structure.
Sources & Citations
- Decile Group. “Venture Studio Funds Are Reshaping Emerging VC”, August 2025.
https://decilegroup.com/articles/venture-studio-funds-emerging-vc - InNiches. Family Offices & Venture Studios: 2025 Report
https://inniches.com/family-office-venture-studio-research-2025 - Emerging Technology Center (ETC Baltimore) – Studio Overview and News.
https://www.etcbaltimore.com/news - Persephoni BioPartners – Strategic Sponsorship Announcement.
https://persephonibio.com/media/persephoni-launches-strategic-sponsorship-with-brightedge - Loud Ventures & Persephoni Biopartners Partnership Release.
https://www.einpresswire.com/article/803156512/loud-ventures-and-persephoni-biopartners-llc-announce-strategic-partnership-to-transform-therapeutic-innovation - Linden Lake Labs – Corporate Overview.
https://lindenlakelabs.com/ - Concept Bio,
https://www.concept.bio/
